Farallon Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Farallon Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$68.2K	Sell	21,438 -21,787	-50%	-$85.4K	﹤0.01%	164
2025 Q4	$186K	Hold	43,225	–	–	﹤0.01%	138
2025 Q3	$1.68M	Hold	43,225	–	–	0.01%	82
2025 Q2	$1.01M	Sell	43,225 -3	-0%	-$71	﹤0.01%	90
2025 Q1	$658K	Hold	43,228	–	–	﹤0.01%	94
2024 Q4	$794K	Sell	43,228 -1	-0%	-$11	﹤0.01%	100
2024 Q3	$479K	Hold	43,229	–	–	﹤0.01%	109
2024 Q2	$402K	Hold	43,229	–	–	﹤0.01%	113
2024 Q1	$1.42M	Hold	43,229	–	–	0.01%	117
2023 Q4	$1.16M	Sell	43,229 -3,065	-7%	-$127K	0.01%	104
2023 Q3	$2.8M	Hold	46,294	–	–	0.01%	105
2023 Q2	$4.72M	Sell	46,294 -9,133	-16%	-$1.26M	0.02%	105
2023 Q1	$9.8M	Sell	55,427 -2,190	-4%	-$733K	0.05%	102
2022 Q4	$22.3M	Sell	57,617 -11,827	-17%	-$4.49M	0.13%	80
2022 Q3	$23.4M	Hold	69,444	–	–	0.13%	96
2022 Q2	$22.8M	Hold	69,444	–	–	0.12%	95
2022 Q1	$30.4M	Buy	69,444 +13,888	+25%	+$5.7M	0.15%	82
2021 Q4	$24.4M	Hold	55,556	–	–	0.12%	85
2021 Q3	$30.9M	Hold	55,556	–	–	0.14%	86
2021 Q2	$28.5M	Sell	55,556 -12,916	-19%	-$8.18M	0.12%	89
2021 Q1	$53.5M	Hold	68,472	–	–	0.27%	70
2020 Q4	$37.3M	Buy	68,472 +5,972	+10%	+$3.13M	0.22%	73
2020 Q3	$28.6M	Sell	62,500 -1,389	-2%	-$807K	0.2%	78
2020 Q2	$39.3M	Hold	63,889	–	–	0.31%	64
2020 Q1	$30.4M	Hold	63,889	–	–	0.26%	56
2019 Q4	$37.1M	Buy	63,889 +4,167	+7%	+$2.92M	0.25%	64
2019 Q3	$39.3M	Buy	59,722 +33,296	+126%	+$27.7M	0.3%	51
2019 Q2	$20.5M	Buy	+26,426	New	+$18.6M	0.13%	77

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Farallon Capital Management's TVRD Position: Q1 2026 in Review

Farallon Capital Management reduced its Tvardi Therapeutics (TVRD) stake by 50% in Q1 2026, selling an estimated $85.4K and leaving 21,438 shares worth $68.2K. The position accounts for ﹤0.01% of the portfolio, ranked #164.

Farallon Capital Management first reported a position in TVRD in Q2 2019 and has held it in 28 quarters since. The position peaked at $53.5M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

Farallon Capital Management held 21,438 shares of Tvardi Therapeutics worth $68.2K as of Q1 2026.
Farallon Capital Management sold 21,787 Tvardi Therapeutics shares in Q1 2026, an estimated $85.4K.
Tvardi Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #164 holding.
Farallon Capital Management first reported a position in Tvardi Therapeutics in Q2 2019 and has held it in 28 quarters since.
Farallon Capital Management's Tvardi Therapeutics position peaked at $53.5M in Q1 2021.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.